Shionogi & Co., Ltd.
Q1 FY2027 Financial Results Supplement
For Q1 of the 2026 fiscal year, revenue was 163.3 billion yen, a substantial year‑over‑year increase; full-year guidance is around 700.0 billion yen, with progress at 23.3%. Major drivers are higher overseas subsidiaries, exports, and the impact of the ViiV Healthcare equity-method affiliate. Operating income was 66.9 billion yen year over year, quarterly net income was 97.7 billion yen. The Barber Edarabon business succession led to significant increases in tangible and intangible assets.
Key Figures
- Revenue: 1,633 (対前期増減額 635, 対前期増減率 63.7%)
- Operating Income: 669 (対前期増減額 318, 増減率 90.6%)
- Quarterly Net Income: 977 (対前期増減額 584, 増減率 148.3%)
AI要約
Overview of Results
Consolidated revenue for Q1 reached 163.3 billion yen, marking a substantial increase year over year, driven by stronger contributions from domestic and international pharmaceutical businesses and royalty income. Operating income was 66.9 billion yen, and quarterly net income was 97.7 billion yen. The effects of equity-method investments in ViiV Healthcare and the structural impact of the Edarabon business succession were primary factors. The full-year guidance is 700.0 billion yen, with progress at 23.3%.
Outlook and Focus Areas
The Edarabon business succession has led to large increases in intangible assets and goodwill, influencing the financial structure. It remains to be seen whether overseas sales growth will continue and how the JT Pharmaceutical business and Torii Pharmaceutical consolidation will affect future cost structure. Also to monitor are progress toward the full-year forecast and currency effects.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
